Scholarlink

Introduction <p>The role of sentinel lymph node biopsy (SLNB) in clinically node-negative melanoma has been questioned in the era of effective adjuvant immunotherapy. We evaluated the staging and prognostic value of SLNB in a single-centre cohort, with emphasis on patients with “high-risk” primary tumours.</p> Methods <p>We retrospectively analysed 300 consecutive patients with cutaneous melanoma who underwent wide local excision with SLNB at a tertiary melanoma centre (April 2018–April 2023). Patients were stratified by AJCC 8th edition T stage into low-risk (T1–T3a) and high-risk (T3b–T4b) groups. Outcomes included SLN positivity, recurrence, and disease-free survival (DFS). DFS was assessed using Kaplan–Meier methods with log-rank testing; restricted mean survival time (RMST) was calculated to 3 years. In high-risk patients with available data, the Melanoma Institute of Australia sentinel node risk tool was evaluated for discrimination and calibration.</p> Results <p>Median age was 60.7 years and 51.3% were male. Overall SLN positivity was 22.0% (66/300) and was higher in high-risk than low-risk melanoma (31.5% [28/89] vs. 18.0% [38/211], <i>P</i> = 0.009). Recurrence occurred in 16.0% (48/300), more frequently in high-risk patients (31.5% vs. 9.5%). Estimated DFS at 1 and 3 years was 96.6% and 81.8% for low-risk melanoma versus 87.9% and 68.6% for high-risk melanoma (log-rank <i>P</i> &lt; 0.001); RMST to 3 years favoured the low-risk group by 115.9 days (95% CI 20.8–213.3). SLNB resulted in substantial stage migration in high-risk clinically node-negative patients, identifying pathological stage IIIC disease in 31.5% (28/89) who would otherwise be classified as stage IIB/IIC.</p> Conclusion <p>SLNB continues to provide clinically important staging and prognostic information, particularly in high-risk clinically node-negative melanoma where occult nodal disease is common. Omitting SLNB risks systematic understaging and loss of prognostic resolution.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sentinel lymph node status and oncological outcomes of high-risk and low-risk cutaneous primary melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Hesham S. Mohamed,
  • Michael G. Fadel,
  • Michelle J. Wilkinson,
  • Olympia Hadjicosta,
  • Justin Weir,
  • Kieran Power,
  • Andrew J. Hayes,
  • Myles J. Smith

摘要

Introduction

The role of sentinel lymph node biopsy (SLNB) in clinically node-negative melanoma has been questioned in the era of effective adjuvant immunotherapy. We evaluated the staging and prognostic value of SLNB in a single-centre cohort, with emphasis on patients with “high-risk” primary tumours.

Methods

We retrospectively analysed 300 consecutive patients with cutaneous melanoma who underwent wide local excision with SLNB at a tertiary melanoma centre (April 2018–April 2023). Patients were stratified by AJCC 8th edition T stage into low-risk (T1–T3a) and high-risk (T3b–T4b) groups. Outcomes included SLN positivity, recurrence, and disease-free survival (DFS). DFS was assessed using Kaplan–Meier methods with log-rank testing; restricted mean survival time (RMST) was calculated to 3 years. In high-risk patients with available data, the Melanoma Institute of Australia sentinel node risk tool was evaluated for discrimination and calibration.

Results

Median age was 60.7 years and 51.3% were male. Overall SLN positivity was 22.0% (66/300) and was higher in high-risk than low-risk melanoma (31.5% [28/89] vs. 18.0% [38/211], P = 0.009). Recurrence occurred in 16.0% (48/300), more frequently in high-risk patients (31.5% vs. 9.5%). Estimated DFS at 1 and 3 years was 96.6% and 81.8% for low-risk melanoma versus 87.9% and 68.6% for high-risk melanoma (log-rank P < 0.001); RMST to 3 years favoured the low-risk group by 115.9 days (95% CI 20.8–213.3). SLNB resulted in substantial stage migration in high-risk clinically node-negative patients, identifying pathological stage IIIC disease in 31.5% (28/89) who would otherwise be classified as stage IIB/IIC.

Conclusion

SLNB continues to provide clinically important staging and prognostic information, particularly in high-risk clinically node-negative melanoma where occult nodal disease is common. Omitting SLNB risks systematic understaging and loss of prognostic resolution.